Scolaris Content Display Scolaris Content Display

Cochrane Database of Systematic Reviews

Epidermal growth factor receptor blockers for the treatment of ovarian cancer

This is not the most recent version

view the current version 15 October 2018

Information

DOI:
https://doi.org/10.1002/14651858.CD007927.pub2Copy DOI
Database:
  1. Cochrane Database of Systematic Reviews
Version published:
  1. 07 October 2009see what's new
Type:
  1. Intervention
Stage:
  1. Protocol
Cochrane Editorial Group:

  1. Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group

Copyright:
  1. Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Article metrics

Altmetric:

Cited by:

Cited 0 times via Crossref Cited-by Linking

Collapse

Authors

  • Krishnayan Haldar

    Correspondence to: Oxford Gynaecological Oncology Centre, Level 0, Oxford Cancer and Haematology Centre, Oxford, UK

    [email protected]

  • Kezia Gaitskell

    North Central Thames Foundation School, UCL Medical School, London, UK

  • Andrew Bryant

    Institute of Health and Society, Newcastle University, Newcastle upon Tyne, UK

  • Heather O Dickinson

    Institute of Health and Society, Newcastle University, Newcastle upon Tyne, UK

  • Shibani Nicum

    NHS Department of Oncology, Level 2, Oxford Cancer and Haematology Centre, Oxford, UK

  • Sean Kehoe

    Oxford Gynaecological Oncology Centre, Level 0, Oxford Cancer and Haematology Centre, Oxford, UK

  • Jo Morrison

    Nuffield Department of Obstetrics and Gynaecology, University of Oxford, Oxford, UK

Contributions of authors

The protocol was written by JM and KG, with significant input from HD,AB and SN. SK and JM had the initial concept for the title and approved the final version of the protocol.

Sources of support

Internal sources

  • No sources of support supplied

External sources

  • NIHR CCRCD, UK.

    JM is a Walport Clinical Lecturer, 50% academic component is funded by NIHR CCRCD

  • Macmillan Cancer Supoort, UK.

    JM is a subspecialist trainee in gynaecological oncology. This 50% clinical post is funded by a grant from Macmillan Cancer Support.

  • Department of Health, UK.

    NHS Cochrane Collaboration Programme Grant Scheme CPG‐506

Declarations of interest

None

Acknowledgements

We thank Chris Williams for clinical and editorial advice, Jane Hayes for advice on the search strategy and Gail Quinn and Clare Jess for their contribution to the editorial process. We thank the referees for their many helpful suggestions.

Version history

Published

Title

Stage

Authors

Version

2018 Oct 15

Epidermal growth factor receptor blockers for the treatment of ovarian cancer

Review

Jo Morrison, Clemens Thoma, Richard J Goodall, Thomas J Lyons, Kezia Gaitskell, Alison J Wiggans, Andrew Bryant

https://doi.org/10.1002/14651858.CD007927.pub4

2011 Oct 05

Epidermal growth factor receptor blockers for the treatment of ovarian cancer

Review

Krishnayan Haldar, Kezia Gaitskell, Andrew Bryant, Shibani Nicum, Sean Kehoe, Jo Morrison

https://doi.org/10.1002/14651858.CD007927.pub3

2009 Oct 07

Epidermal growth factor receptor blockers for the treatment of ovarian cancer

Protocol

Krishnayan Haldar, Kezia Gaitskell, Andrew Bryant, Heather O Dickinson, Shibani Nicum, Sean Kehoe, Jo Morrison

https://doi.org/10.1002/14651858.CD007927.pub2

2009 Jul 08

Epidermal growth factor receptor blockers for the treatment of ovarian cancer

Protocol

Kezia Gaitskell, Igor Martinek, Shibani Nicum, Sean Kehoe, Jo Morrison

https://doi.org/10.1002/14651858.CD007927

Keywords

MeSH

Medical Subject Headings (MeSH) Keywords

Medical Subject Headings Check Words

Female; Humans;

PICOs

Population
Intervention
Comparison
Outcome

The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.

See more on using PICO in the Cochrane Handbook.

(A) The EGFR is a transmembrane protein. (B) Following binding to its ligand, EGF, the EGFR is stimulated and develops tyrosine kinase activity. (C) Tyrosine kinase activity sets of a sequence of downstream events that lead to stimulation of cell growth. (D) EGFR activity can be blocked by antibodies, which prevent EGF binding to the receptor, or using chemicals, which inhibit the tyrosine kinase enzyme activity.
Figures and Tables -
Figure 1

(A) The EGFR is a transmembrane protein. (B) Following binding to its ligand, EGF, the EGFR is stimulated and develops tyrosine kinase activity. (C) Tyrosine kinase activity sets of a sequence of downstream events that lead to stimulation of cell growth. (D) EGFR activity can be blocked by antibodies, which prevent EGF binding to the receptor, or using chemicals, which inhibit the tyrosine kinase enzyme activity.

Navigate to figure in ProtocolOpen in new tab